指南与共识泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

COVID-19疫情期间前列腺癌放疗推荐

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.
指南 / 共识 · Adv Radiat Oncol · 2020-04-01

美国与英国放射肿瘤学家快速系统综述并达成共识,提出RADS框架(远程访视、避免、推迟、缩短放疗),按NCCN风险组为临床淋巴结阳性、前列腺切除术后、寡转移及低瘤负荷M1前列腺癌给出放疗管理推荐。

要点

  • 资源允许时所有分期均推荐远程医疗咨询与复诊。
  • 极低危、低危及有利中危可避免或推迟放疗至安全时。
  • 不利中危、高危、临床淋巴结阳性、术后复发、寡转移及低瘤负荷M1可先用4–6个月新辅助激素治疗。

核心结论

  • 所有已识别的 prostate cancer 分期均可减少资源使用,RADS框架可推广至其他病种以辅助全球大流行中的决策。

研究设计与样本

  • 美国与英国放射肿瘤学家快速开展系统综述,并达成安全管理的推荐共识,创建RADS框架(远程访视、避免、推迟、缩短放疗)。

主要发现

  • 所有前列腺癌分期在资源/人员可用时推荐远程医疗咨询与复诊。
  • 根据疾病分期,咨询与复诊延迟1至6个月被视为安全。
  • 极低危、低危及有利中危可避免或推迟放疗至安全时。
  • 不利中危、高危、临床淋巴结阳性、术后复发、寡转移及低瘤负荷M1可按需接受4至6个月新辅助激素治疗。

关键数值与推荐

  • 局限期、寡转移及低瘤负荷M1首选超低分割放疗。
  • 前列腺切除术后及临床淋巴结阳性疾病首选中等低分割放疗。
  • 挽救性放疗优于辅助放疗。

临床怎么用

  • 按NCCN风险组分层,利用RADS框架决定远程访视、避免、推迟或缩短放疗。
  • 资源紧张时优先对有利风险患者避免或推迟放疗,对不利风险患者先用新辅助激素治疗。
  • 优先选择超低分割或中等低分割方案以缩短疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020. PMID: 32292839. doi:10.1016/j.adro.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。